- Home
- GDTC
as 01-17-2025 4:00pm EST
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
| Founded: | 2018 | Country: | Singapore |
| Employees: | N/A | City: | N/A |
| Market Cap: | 33.4M | IPO Year: | 2023 |
| Target Price: | $5.00 | AVG Volume (30 days): | 597.0K |
| Analyst Decision: | Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.20 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.20 - $4.30 | Next Earning Date: | 01-01-0001 |
| Revenue: | $330,254 | Revenue Growth: | -21.95% |
| Revenue Growth (this year): | 14.71% | Revenue Growth (next year): | -8.93% |
Latest CytoMed Therapeutics Limited News
GDTC Breaking Stock News: Dive into GDTC Ticker-Specific Updates for Smart Investing
TipRanks
12 days ago
CytoMed and SunAct Collaborate on Cancer Immunotherapy Trials in India
MT Newswires
12 days ago
Top Premarket Decliners
Clinical Trials Arena
12 days ago
CytoMed Therapeutics and SunAct to conduct solid tumour treatment trial in India
MT Newswires
13 days ago
Sector Update: Health Care Stocks Edge Higher Premarket Monday
MT Newswires
13 days ago
CytoMed, SunAct Cancer Institute Sign 5-Year Collaboration Deal for Phase 2 Clinical Trial in India
GlobeNewswire
13 days ago
CytoMed Therapeutics signs Business & Research Collaboration Agreement with India’s SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers in a proposed Phase 2 clinical trial in India
Simply Wall St.
16 days ago
CytoMed Therapeutics Leads 3 US Penny Stocks To Consider
Simply Wall St.
a month ago
CytoMed Therapeutics And 2 Other US Penny Stocks To Watch
Compare GDTC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GDTC CytoMed Therapeutics Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.